Drug-Induced Torsades de Pointes and Implications for Drug Development
Autor: | Charles Antzelevitch, Dan M. Roden, Jeremy N. Ruskin, Louis R. Cantilena, Silvia G. Priori, Michael C. Sanguinetti, Robert R. Fenichel, Marek Malik, Raymond J. Lipicky |
---|---|
Rok vydání: | 2004 |
Předmět: |
Drug
medicine.medical_specialty Long QT syndrome media_common.quotation_subject Torsades de pointes Risk Assessment QT interval Article Electrocardiography Torsades de Pointes Physiology (medical) Internal medicine Humans Medicine Repolarization cardiovascular diseases Adverse effect Intensive care medicine media_common business.industry Drugs Investigational medicine.disease Electrophysiology Long QT Syndrome Drug development Cardiology Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents |
Zdroj: | Journal of Cardiovascular Electrophysiology. 15:475-495 |
ISSN: | 1540-8167 1045-3873 |
DOI: | 10.1046/j.1540-8167.2004.03534.x |
Popis: | Torsades de pointes is a potentially lethal arrhythmia that occasionally appears as an adverse effect of pharmacotherapy. Recently developed understanding of the underlying electrophysiology allows better estimation of the drug-induced risks and explains the failures of older approaches through the surface ECG. This article expresses a consensus reached by an independent academic task force on the physiologic understanding of drug-induced repolarization changes, their preclinical and clinical evaluation, and the risk-to-benefit interpretation of drug-induced torsades de pointes. The consensus of the task force includes suggestions on how to evaluate the risk of torsades within drug development programs. Individual sections of the text discuss the techniques and limitations of methods directed at drug-related ion channel phenomena, investigations aimed at action potentials changes, preclinical studies of phenomena seen only in the whole (or nearly whole) heart, and interpretation of human ECGs obtained in clinical studies. The final section of the text discusses drug-induced torsades within the larger evaluation of drug-related risks and benefits. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |